A phase /11 study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G.CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients
1998

Study on Chemotherapy and Blood Cell Support

Sample size: 40 publication Evidence: moderate

Author Information

Author(s): R de Wit, WHJ Kruit, CHJ Lamers, MB van 't Veer, AA Luyten, V van Beurden, M Harteveld, ASTh Planting, PIM Schmitz, G Stoter, RLH Bolhuis, J Verweij

Primary Institution: Rotterdam Cancer Institute and University Hospital Rotterdam

Hypothesis

Does the use of G-CSF and haematopoietic progenitor cells in whole blood reduce bone marrow toxicity during chemotherapy?

Conclusion

The combined use of G-CSF and haematopoietic progenitor cells in whole blood does not significantly reduce bone marrow toxicity compared to G-CSF alone.

Supporting Evidence

  • The median number of CD34+ cells increased significantly after the second cycle.
  • No neutropenic fever was encountered in the second cohort.
  • Despite increased doses of ifosfamide, myelotoxicity remained similar to lower doses without PBPCs.

Takeaway

The study looked at whether using special blood cells during chemotherapy helps patients feel better, but it didn't really make a difference.

Methodology

Patients received up to six cycles of chemotherapy with G-CSF support, and some had additional blood cells reinfused.

Limitations

The study did not show a measurable reduction in toxicity, and the reconstitutive potential of the blood cells was limited.

Participant Demographics

Median age was 55 years, with a range from 19 to 70 years; included various types of metastatic solid tumors.

Statistical Information

P-Value

0.01

Statistical Significance

p=0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication